ID   CSK21_HUMAN             Reviewed;         391 AA.
AC   P68400; B4DYS6; D3DVV8; P19138; P20426; Q14013; Q5U065;
DT   23-NOV-2004, integrated into UniProtKB/Swiss-Prot.
DT   23-NOV-2004, sequence version 1.
DT   10-MAY-2017, entry version 153.
DE   RecName: Full=Casein kinase II subunit alpha;
DE            Short=CK II alpha;
DE            EC=2.7.11.1;
GN   Name=CSNK2A1; Synonyms=CK2A1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2752008; DOI=10.1021/bi00435a066;
RA   Meisner H., Heller-Harrison R., Buxton J., Czech M.P.;
RT   "Molecular cloning of the human casein kinase II alpha subunit.";
RL   Biochemistry 28:4072-4076(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2174700; DOI=10.1021/bi00488a034;
RA   Lozeman F.J., Litchfield D.W., Piening C., Takio K., Walsh K.A.,
RA   Krebs E.G.;
RT   "Isolation and characterization of human cDNA clones encoding the
RT   alpha and the alpha' subunits of casein kinase II.";
RL   Biochemistry 29:8436-8447(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1).
RX   PubMed=8420794; DOI=10.1016/0014-5793(93)81197-8;
RA   Devilat I., Carvallo P.;
RT   "Structure and sequence of an intronless gene for human casein kinase
RT   II-alpha subunit.";
RL   FEBS Lett. 316:114-118(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (OCT-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=19054851; DOI=10.1038/nmeth.1273;
RA   Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R.,
RA   Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y.,
RA   Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B.,
RA   Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H.,
RA   Maruyama Y., Matsuo K., Minami K., Mitsubori M., Mori M.,
RA   Morishita R., Murase A., Nishikawa A., Nishikawa S., Okamoto T.,
RA   Sakagami N., Sakamoto Y., Sasaki Y., Seki T., Sono S., Sugiyama A.,
RA   Sumiya T., Takayama T., Takayama Y., Takeda H., Togashi T., Yahata K.,
RA   Yamada H., Yanagisawa Y., Endo Y., Imamoto F., Kisu Y., Tanaka S.,
RA   Isogai T., Imai J., Watanabe S., Nomura N.;
RT   "Human protein factory for converting the transcriptome into an in
RT   vitro-expressed proteome.";
RL   Nat. Methods 5:1011-1017(2008).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M.,
RA   Beasley O.P., Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J.,
RA   Buck D., Burrill W.D., Butler A.P., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M., Clark G., Clark L.N., Clark S.Y., Clee C.M.,
RA   Clegg S., Cobley V.E., Collier R.E., Connor R.E., Corby N.R.,
RA   Coulson A., Coville G.J., Deadman R., Dhami P.D., Dunn M.,
RA   Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H.,
RA   Rice C.M., Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S.,
RA   Skuce C.D., Smith M.L., Soderlund C., Steward C.A., Sulston J.E.,
RA   Swann R.M., Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A.,
RA   Tracey A., Tromans A.C., Vaudin M., Wall M., Wallis J.M.,
RA   Whitehead S.L., Whittaker P., Willey D.L., Williams L., Williams S.A.,
RA   Wilming L., Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S.,
RA   Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lung, Muscle, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   PHOSPHORYLATION AT THR-344; THR-360; SER-362 AND SER-370.
RX   PubMed=7592773; DOI=10.1074/jbc.270.43.25872;
RA   Bosc D.G., Slominski E., Sichler C., Litchfield D.W.;
RT   "Phosphorylation of casein kinase II by p34cdc2. Identification of
RT   phosphorylation sites using phosphorylation site mutants in vitro.";
RL   J. Biol. Chem. 270:25872-25878(1995).
RN   [11]
RP   FUNCTION, AND INTERACTION WITH SSRP1 AND SUPT16H.
RX   PubMed=11239457; DOI=10.1016/S1097-2765(01)00176-9;
RA   Keller D.M., Zeng X., Wang Y., Zhang Q.H., Kapoor M., Shu H.,
RA   Goodman R., Lozano G., Zhao Y., Lu H.;
RT   "A DNA damage-induced p53 serine 392 kinase complex contains CK2,
RT   hSpt16, and SSRP1.";
RL   Mol. Cell 7:283-292(2001).
RN   [12]
RP   FUNCTION IN CELL CYCLE.
RX   PubMed=11704824; DOI=10.1038/sj.onc.1204894;
RA   Sayed M., Pelech S., Wong C., Marotta A., Salh B.;
RT   "Protein kinase CK2 is involved in G2 arrest and apoptosis following
RT   spindle damage in epithelial cells.";
RL   Oncogene 20:6994-7005(2001).
RN   [13]
RP   INTERACTION WITH SSRP1 AND SUPT16H.
RX   PubMed=12393879; DOI=10.1074/jbc.M209820200;
RA   Keller D.M., Lu H.;
RT   "p53 serine 392 phosphorylation increases after UV through induction
RT   of the assembly of the CK2.hSPT16.SSRP1 complex.";
RL   J. Biol. Chem. 277:50206-50213(2002).
RN   [14]
RP   FUNCTION IN APOPTOSIS.
RX   PubMed=16193064; DOI=10.1038/sj.emboj.7600827;
RA   Shin S., Lee Y., Kim W., Ko H., Choi H., Kim K.;
RT   "Caspase-2 primes cancer cells for TRAIL-mediated apoptosis by
RT   processing procaspase-8.";
RL   EMBO J. 24:3532-3542(2005).
RN   [15]
RP   INTERACTION WITH RNPS1.
RX   PubMed=15684395; DOI=10.1128/MCB.25.4.1446-1457.2005;
RA   Trembley J.H., Tatsumi S., Sakashita E., Loyer P., Slaughter C.A.,
RA   Suzuki H., Endo H., Kidd V.J., Mayeda A.;
RT   "Activation of pre-mRNA splicing by human RNPS1 is regulated by CK2
RT   phosphorylation.";
RL   Mol. Cell. Biol. 25:1446-1457(2005).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-370, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [17]
RP   FUNCTION IN CELL CYCLE.
RX   PubMed=19188443; DOI=10.1128/MCB.01563-08;
RA   St-Denis N.A., Derksen D.R., Litchfield D.W.;
RT   "Evidence for regulation of mitotic progression through temporal
RT   phosphorylation and dephosphorylation of CK2alpha.";
RL   Mol. Cell. Biol. 29:2068-2081(2009).
RN   [18]
RP   REVIEW ON FUNCTION.
RX   PubMed=12631575; DOI=10.1096/fj.02-0473rev;
RA   Meggio F., Pinna L.A.;
RT   "One-thousand-and-one substrates of protein kinase CK2?";
RL   FASEB J. 17:349-368(2003).
RN   [19]
RP   REVIEW ON STRUCTURE.
RX   PubMed=19387553; DOI=10.1007/s00018-009-9149-8;
RA   Niefind K., Raaf J., Issinger O.G.;
RT   "Protein kinase CK2 in health and disease: Protein kinase CK2: from
RT   structures to insights.";
RL   Cell. Mol. Life Sci. 66:1800-1816(2009).
RN   [20]
RP   REVIEW ON FUNCTION.
RX   PubMed=19387552; DOI=10.1007/s00018-009-9150-2;
RA   St-Denis N.A., Litchfield D.W.;
RT   "Protein kinase CK2 in health and disease: From birth to death: the
RT   role of protein kinase CK2 in the regulation of cell proliferation and
RT   survival.";
RL   Cell. Mol. Life Sci. 66:1817-1829(2009).
RN   [21]
RP   REVIEW ON FUNCTION.
RX   PubMed=19387551; DOI=10.1007/s00018-009-9151-1;
RA   Filhol O., Cochet C.;
RT   "Protein kinase CK2 in health and disease: Cellular functions of
RT   protein kinase CK2: a dynamic affair.";
RL   Cell. Mol. Life Sci. 66:1830-1839(2009).
RN   [22]
RP   REVIEW ON FUNCTION IN REGULATION OF HSP90.
RX   PubMed=19387550; DOI=10.1007/s00018-009-9152-0;
RA   Miyata Y.;
RT   "Protein kinase CK2 in health and disease: CK2: the kinase controlling
RT   the Hsp90 chaperone machinery.";
RL   Cell. Mol. Life Sci. 66:1840-1849(2009).
RN   [23]
RP   REVIEW ON FUNCTION IN WNT SIGNALING.
RX   PubMed=19387549; DOI=10.1007/s00018-009-9153-z;
RA   Dominguez I., Sonenshein G.E., Seldin D.C.;
RT   "Protein kinase CK2 in health and disease: CK2 and its role in Wnt and
RT   NF-kappaB signaling: linking development and cancer.";
RL   Cell. Mol. Life Sci. 66:1850-1857(2009).
RN   [24]
RP   INTERACTION WITH SNAI1.
RX   PubMed=19923321; DOI=10.1091/mbc.E09-06-0504;
RA   MacPherson M.R., Molina P., Souchelnytskyi S., Wernstedt C.,
RA   Martin-Perez J., Portillo F., Cano A.;
RT   "Phosphorylation of serine 11 and serine 92 as new positive regulators
RT   of human Snail1 function: potential involvement of casein kinase-2 and
RT   the cAMP-activated kinase protein kinase A.";
RL   Mol. Biol. Cell 21:244-253(2010).
RN   [25]
RP   FUNCTION, CATALYTIC ACTIVITY, AND INTERACTION WITH PML.
RX   PubMed=20625391; DOI=10.1371/journal.pone.0011418;
RA   Hung M.S., Lin Y.C., Mao J.H., Kim I.J., Xu Z., Yang C.T.,
RA   Jablons D.M., You L.;
RT   "Functional polymorphism of the CK2alpha intronless gene plays
RT   oncogenic roles in lung cancer.";
RL   PLoS ONE 5:E11418-E11418(2010).
RN   [26]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [28]
RP   FUNCTION, AND INTERACTION WITH PML.
RX   PubMed=22406621; DOI=10.1158/0008-5472.CAN-11-3159;
RA   Rabellino A., Carter B., Konstantinidou G., Wu S.Y., Rimessi A.,
RA   Byers L.A., Heymach J.V., Girard L., Chiang C.M., Teruya-Feldstein J.,
RA   Scaglioni P.P.;
RT   "The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its
RT   oncogenic counterpart PML-RARA.";
RL   Cancer Res. 72:2275-2284(2012).
RN   [29]
RP   FUNCTION, INTERACTION WITH CCAR2, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=24962073; DOI=10.1002/ijc.29043;
RA   Bae J.S., Park S.H., Kim K.M., Kwon K.S., Kim C.Y., Lee H.K.,
RA   Park B.H., Park H.S., Lee H., Moon W.S., Chung M.J., Sylvester K.G.,
RA   Jang K.Y.;
RT   "CK2alpha phosphorylates DBC1 and is involved in the progression of
RT   gastric carcinoma and predicts poor survival of gastric carcinoma
RT   patients.";
RL   Int. J. Cancer 136:797-809(2015).
RN   [30]
RP   INVOLVEMENT IN OCNDS, AND VARIANTS OCNDS GLN-47; SER-50; GLY-175 AND
RP   ARG-198.
RX   PubMed=27048600; DOI=10.1007/s00439-016-1661-y;
RA   Okur V., Cho M.T., Henderson L., Retterer K., Schneider M.,
RA   Sattler S., Niyazov D., Azage M., Smith S., Picker J., Lincoln S.,
RA   Tarnopolsky M., Brady L., Bjornsson H.T., Applegate C., Dameron A.,
RA   Willaert R., Baskin B., Juusola J., Chung W.K.;
RT   "De novo mutations in CSNK2A1 are associated with neurodevelopmental
RT   abnormalities and dysmorphic features.";
RL   Hum. Genet. 135:699-705(2016).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) OF 1-337, AND SUBUNIT.
RX   PubMed=11092945; DOI=10.1107/S0907444900013627;
RA   Niefind K., Guerra B., Ermakowa I., Issinger O.G.;
RT   "Crystallization and preliminary characterization of crystals of human
RT   protein kinase CK2.";
RL   Acta Crystallogr. D 56:1680-1684(2000).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) OF 1-337 IN COMPLEX WITH CSNK2B,
RP   AND SUBUNIT.
RX   PubMed=11574463; DOI=10.1093/emboj/20.19.5320;
RA   Niefind K., Guerra B., Ermakowa I., Issinger O.G.;
RT   "Crystal structure of human protein kinase CK2: insights into basic
RT   properties of the CK2 holoenzyme.";
RL   EMBO J. 20:5320-5331(2001).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 1-329.
RX   PubMed=14646071; DOI=10.1107/S0907444903018900;
RA   Pechkova E., Zanotti G., Nicolini C.;
RT   "Three-dimensional atomic structure of a catalytic subunit mutant of
RT   human protein kinase CK2.";
RL   Acta Crystallogr. D 59:2133-2139(2003).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 2-335.
RX   PubMed=12860116; DOI=10.1016/S0022-2836(03)00638-7;
RA   Ermakova I., Boldyreff B., Issinger O.G., Niefind K.;
RT   "Crystal structure of a C-terminal deletion mutant of human protein
RT   kinase CK2 catalytic subunit.";
RL   J. Mol. Biol. 330:925-934(2003).
CC   -!- FUNCTION: Catalytic subunit of a constitutively active
CC       serine/threonine-protein kinase complex that phosphorylates a
CC       large number of substrates containing acidic residues C-terminal
CC       to the phosphorylated serine or threonine. Regulates numerous
CC       cellular processes, such as cell cycle progression, apoptosis and
CC       transcription, as well as viral infection. May act as a regulatory
CC       node which integrates and coordinates numerous signals leading to
CC       an appropriate cellular response. During mitosis, functions as a
CC       component of the p53/TP53-dependent spindle assembly checkpoint
CC       (SAC) that maintains cyclin-B-CDK1 activity and G2 arrest in
CC       response to spindle damage. Also required for p53/TP53-mediated
CC       apoptosis, phosphorylating 'Ser-392' of p53/TP53 following UV
CC       irradiation. Can also negatively regulate apoptosis.
CC       Phosphorylates the caspases CASP9 and CASP2 and the apoptotic
CC       regulator NOL3. Phosphorylation protects CASP9 from cleavage and
CC       activation by CASP8, and inhibits the dimerization of CASP2 and
CC       activation of CASP8. Regulates transcription by direct
CC       phosphorylation of RNA polymerases I, II, III and IV. Also
CC       phosphorylates and regulates numerous transcription factors
CC       including NF-kappa-B, STAT1, CREB1, IRF1, IRF2, ATF1, SRF, MAX,
CC       JUN, FOS, MYC and MYB. Phosphorylates Hsp90 and its co-chaperones
CC       FKBP4 and CDC37, which is essential for chaperone function.
CC       Regulates Wnt signaling by phosphorylating CTNNB1 and the
CC       transcription factor LEF1. Acts as an ectokinase that
CC       phosphorylates several extracellular proteins. During viral
CC       infection, phosphorylates various proteins involved in the viral
CC       life cycles of EBV, HSV, HBV, HCV, HIV, CMV and HPV.
CC       Phosphorylates PML at 'Ser-565' and primes it for ubiquitin-
CC       mediated degradation. Plays an important role in the circadian
CC       clock function by phosphorylating ARNTL/BMAL1 at 'Ser-90' which is
CC       pivotal for its interaction with CLOCK and which controls CLOCK
CC       nuclear entry (PubMed:11239457, PubMed:11704824, PubMed:16193064,
CC       PubMed:19188443, PubMed:20625391, PubMed:22406621). Phosphorylates
CC       CCAR2 at 'Thr-454' in gastric carcinoma tissue (PubMed:24962073).
CC       {ECO:0000269|PubMed:11239457, ECO:0000269|PubMed:11704824,
CC       ECO:0000269|PubMed:16193064, ECO:0000269|PubMed:19188443,
CC       ECO:0000269|PubMed:20625391, ECO:0000269|PubMed:22406621,
CC       ECO:0000269|PubMed:24962073}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC       {ECO:0000269|PubMed:20625391}.
CC   -!- ENZYME REGULATION: Constitutively active protein kinase whose
CC       activity is not directly affected by phosphorylation. Seems to be
CC       regulated by level of expression and localization.
CC   -!- SUBUNIT: Heterotetramer composed of two catalytic subunits (alpha
CC       chain and/or alpha' chain) and two regulatory subunits (beta
CC       chains). The tetramer can exist as a combination of 2 alpha/2
CC       beta, 2 alpha'/2 beta or 1 alpha/1 alpha'/2 beta subunits. Also
CC       part of a CK2-SPT16-SSRP1 complex composed of SSRP1, SUPT16H,
CC       CSNK2A1, CSNK2A2 and CSNK2B, which forms following UV irradiation.
CC       Interacts with RNPS1. Interacts with SNAI1. Interacts with PML
CC       (isoform PML-12). Interacts with CCAR2.
CC       {ECO:0000269|PubMed:11092945, ECO:0000269|PubMed:11239457,
CC       ECO:0000269|PubMed:11574463, ECO:0000269|PubMed:12393879,
CC       ECO:0000269|PubMed:15684395, ECO:0000269|PubMed:19923321,
CC       ECO:0000269|PubMed:20625391, ECO:0000269|PubMed:22406621,
CC       ECO:0000269|PubMed:24962073}.
CC   -!- INTERACTION:
CC       O00257-3:CBX4; NbExp=2; IntAct=EBI-347804, EBI-4392727;
CC       P19784:CSNK2A2; NbExp=6; IntAct=EBI-347804, EBI-347451;
CC       P67870:CSNK2B; NbExp=17; IntAct=EBI-347804, EBI-348169;
CC       O75822:EIF3J; NbExp=2; IntAct=EBI-347804, EBI-366647;
CC       Q13547:HDAC1; NbExp=2; IntAct=EBI-347804, EBI-301834;
CC       O60282:KIF5C; NbExp=4; IntAct=EBI-347804, EBI-717170;
CC       P43364-2:MAGEA11; NbExp=3; IntAct=EBI-347804, EBI-10178634;
CC       P23511:NFYA; NbExp=3; IntAct=EBI-347804, EBI-389739;
CC       P29590:PML; NbExp=2; IntAct=EBI-347804, EBI-295890;
CC       Q6ZNA4:RNF111; NbExp=4; IntAct=EBI-347804, EBI-2129175;
CC       Q99496:RNF2; NbExp=3; IntAct=EBI-347804, EBI-722416;
CC       Q96EB6:SIRT1; NbExp=4; IntAct=EBI-347804, EBI-1802965;
CC       Q92504:SLC39A7; NbExp=4; IntAct=EBI-347804, EBI-1051105;
CC       Q08945:SSRP1; NbExp=2; IntAct=EBI-347804, EBI-353771;
CC       Q96MF2:STAC3; NbExp=5; IntAct=EBI-347804, EBI-745680;
CC       O75683:SURF6; NbExp=2; IntAct=EBI-347804, EBI-2691252;
CC       Q9NVV9:THAP1; NbExp=5; IntAct=EBI-347804, EBI-741515;
CC       P04637:TP53; NbExp=2; IntAct=EBI-347804, EBI-366083;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:24962073}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P68400-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P68400-2; Sequence=VSP_041925;
CC   -!- TISSUE SPECIFICITY: Expressed in gastric carcinoma tissue and the
CC       expression gradually increases with the progression of the
CC       carcinoma (at protein level). {ECO:0000269|PubMed:24962073}.
CC   -!- PTM: Phosphorylated at Thr-344, Thr-360, Ser-362 and Ser-370 by
CC       CDK1 in prophase and metaphase and dephosphorylated during
CC       anaphase. Phosphorylation does not directly affect casein kinase 2
CC       activity, but may contribute to its regulation by forming binding
CC       sites for interacting proteins and/or targeting it to different
CC       compartments. {ECO:0000269|PubMed:7592773}.
CC   -!- DISEASE: Okur-Chung neurodevelopmental syndrome (OCNDS)
CC       [MIM:617062]: An autosomal dominant neurodevelopmental disorder
CC       characterized by developmental delay, intellectual disability,
CC       behavioral problems, hypotonia, speech problems, microcephaly,
CC       pachygyria and variable dysmorphic features.
CC       {ECO:0000269|PubMed:27048600}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: Can use both ATP and GTP as phosphoryl donors.
CC       Phosphorylation by casein kinase 2 has been estimated to represent
CC       up to one quarter of the eukaryotic phosphoproteome. Casein kinase
CC       2 has been found to be increased at protein level and up-regulated
CC       at the level of enzyme activity in the majority of cancers.
CC       However, elevated levels of casein kinase 2 are present in certain
CC       normal organs such as brain and testes.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr
CC       protein kinase family. CK2 subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J02853; AAA56821.1; -; mRNA.
DR   EMBL; M55265; AAA35503.1; -; mRNA.
DR   EMBL; S53149; ABB72474.1; -; mRNA.
DR   EMBL; X70251; CAA49758.1; -; Genomic_DNA.
DR   EMBL; AK302583; BAG63838.1; -; mRNA.
DR   EMBL; BT019792; AAV38595.1; -; mRNA.
DR   EMBL; AB451279; BAG70093.1; -; mRNA.
DR   EMBL; AL049761; CAB65624.1; -; Genomic_DNA.
DR   EMBL; CH471133; EAX10665.1; -; Genomic_DNA.
DR   EMBL; CH471133; EAX10666.1; -; Genomic_DNA.
DR   EMBL; CH471133; EAX10667.1; -; Genomic_DNA.
DR   EMBL; CH471133; EAX10668.1; -; Genomic_DNA.
DR   EMBL; CH471133; EAX10669.1; -; Genomic_DNA.
DR   EMBL; BC011668; AAH11668.1; -; mRNA.
DR   EMBL; BC053532; AAH53532.1; -; mRNA.
DR   EMBL; BC071167; AAH71167.1; -; mRNA.
DR   CCDS; CCDS13003.1; -. [P68400-1]
DR   CCDS; CCDS13004.1; -. [P68400-2]
DR   PIR; A30319; A30319.
DR   RefSeq; NP_001886.1; NM_001895.3. [P68400-1]
DR   RefSeq; NP_808227.1; NM_177559.2. [P68400-1]
DR   RefSeq; NP_808228.1; NM_177560.2. [P68400-2]
DR   UniGene; Hs.644056; -.
DR   UniGene; Hs.654675; -.
DR   UniGene; Hs.741126; -.
DR   PDB; 1JWH; X-ray; 3.10 A; A/B=1-337.
DR   PDB; 1NA7; X-ray; 2.40 A; A=1-329.
DR   PDB; 1PJK; X-ray; 2.50 A; A=2-335.
DR   PDB; 2PVR; X-ray; 1.60 A; A=2-335.
DR   PDB; 2ZJW; X-ray; 2.40 A; A=1-335.
DR   PDB; 3AMY; X-ray; 2.30 A; A=1-335.
DR   PDB; 3AT2; X-ray; 1.60 A; A=1-335.
DR   PDB; 3AT3; X-ray; 2.60 A; A=1-335.
DR   PDB; 3AT4; X-ray; 2.20 A; A=1-335.
DR   PDB; 3AXW; X-ray; 2.50 A; A=1-335.
DR   PDB; 3BQC; X-ray; 1.50 A; A=1-335.
DR   PDB; 3C13; X-ray; 1.95 A; A=1-335.
DR   PDB; 3FWQ; X-ray; 2.30 A; A/B=1-335.
DR   PDB; 3H30; X-ray; 1.56 A; A/B=1-334.
DR   PDB; 3JUH; X-ray; 1.66 A; A/B=1-335.
DR   PDB; 3MB6; X-ray; 1.75 A; A=1-331.
DR   PDB; 3MB7; X-ray; 1.65 A; A=1-331.
DR   PDB; 3NGA; X-ray; 2.71 A; A/B=1-333.
DR   PDB; 3NSZ; X-ray; 1.30 A; A=2-331.
DR   PDB; 3OWJ; X-ray; 1.85 A; A=1-331.
DR   PDB; 3OWK; X-ray; 1.80 A; A=1-331.
DR   PDB; 3OWL; X-ray; 2.10 A; A=1-331.
DR   PDB; 3PE1; X-ray; 1.60 A; A=1-337.
DR   PDB; 3PE2; X-ray; 1.90 A; A=1-337.
DR   PDB; 3PE4; X-ray; 1.95 A; B/D=340-352.
DR   PDB; 3Q04; X-ray; 1.80 A; A=3-330.
DR   PDB; 3Q9W; X-ray; 1.70 A; A=1-336.
DR   PDB; 3Q9X; X-ray; 2.20 A; A/B=1-336.
DR   PDB; 3Q9Y; X-ray; 1.80 A; A=1-336.
DR   PDB; 3Q9Z; X-ray; 2.20 A; A/B=1-336.
DR   PDB; 3QA0; X-ray; 2.50 A; A/B=1-336.
DR   PDB; 3R0T; X-ray; 1.75 A; A=1-337.
DR   PDB; 3RPS; X-ray; 2.30 A; A/B=1-335.
DR   PDB; 3TAX; X-ray; 1.88 A; B/D=340-352.
DR   PDB; 3U4U; X-ray; 2.20 A; A=1-333.
DR   PDB; 3U87; X-ray; 2.90 A; A/B=1-325.
DR   PDB; 3U9C; X-ray; 3.20 A; A/B=1-335.
DR   PDB; 3W8L; X-ray; 2.40 A; A/B=1-335.
DR   PDB; 3WAR; X-ray; 1.04 A; A=1-335.
DR   PDB; 3WIK; X-ray; 2.00 A; A=1-335.
DR   PDB; 3WIL; X-ray; 2.90 A; A=1-335.
DR   PDB; 3WOW; X-ray; 2.50 A; A=1-335.
DR   PDB; 4DGL; X-ray; 3.00 A; C/D=1-335.
DR   PDB; 4FBX; X-ray; 2.33 A; A=1-335.
DR   PDB; 4GRB; X-ray; 2.15 A; A=1-333.
DR   PDB; 4GUB; X-ray; 2.20 A; A=1-333.
DR   PDB; 4GYW; X-ray; 1.70 A; B/D=340-352.
DR   PDB; 4GYY; X-ray; 1.85 A; B/D=340-352.
DR   PDB; 4GZ3; X-ray; 1.90 A; B/D=340-352.
DR   PDB; 4IB5; X-ray; 2.20 A; A/B/C=1-335.
DR   PDB; 4KWP; X-ray; 1.25 A; A=1-336.
DR   PDB; 4MD7; X-ray; 3.10 A; E/F/G/H=1-391.
DR   PDB; 4MD8; X-ray; 3.30 A; E/F/G/H=1-391.
DR   PDB; 4MD9; X-ray; 3.50 A; E/F/G/H/K/L/M/P=1-336.
DR   PDB; 4NH1; X-ray; 3.30 A; A/B=1-335.
DR   PDB; 4RLL; X-ray; 1.85 A; A=1-335.
DR   PDB; 4UB7; X-ray; 2.10 A; A=1-335.
DR   PDB; 4UBA; X-ray; 3.00 A; A/B=1-335.
DR   PDB; 5B0X; X-ray; 2.30 A; A=1-335.
DR   PDB; 5CLP; X-ray; 1.68 A; A/B=2-329.
DR   PDB; 5CQU; X-ray; 2.35 A; A=1-335.
DR   PDB; 5CQW; X-ray; 2.65 A; A/B=1-335.
DR   PDB; 5CS6; X-ray; 1.88 A; A/B=2-329.
DR   PDB; 5CSH; X-ray; 1.59 A; A/B=2-329.
DR   PDB; 5CSP; X-ray; 1.50 A; A=2-329.
DR   PDB; 5CSV; X-ray; 1.38 A; A=2-329.
DR   PDB; 5CT0; X-ray; 2.01 A; A/B=2-329.
DR   PDB; 5CTP; X-ray; 2.03 A; A/B=2-329.
DR   PDB; 5CU0; X-ray; 2.18 A; A/B=2-329.
DR   PDB; 5CU2; X-ray; 1.71 A; A/B=2-329.
DR   PDB; 5CU3; X-ray; 1.79 A; A/B=2-329.
DR   PDB; 5CU4; X-ray; 1.56 A; A=2-329.
DR   PDB; 5CU6; X-ray; 1.36 A; A=2-329.
DR   PDB; 5CVF; X-ray; 1.63 A; A=2-329.
DR   PDB; 5CVG; X-ray; 1.25 A; A=2-329.
DR   PDB; 5CVH; X-ray; 1.85 A; A/B=2-329.
DR   PDB; 5CX9; X-ray; 1.73 A; A/B=2-329.
DR   PDB; 5H8B; X-ray; 2.55 A; A/B=1-333.
DR   PDB; 5H8E; X-ray; 2.15 A; A/B=1-333.
DR   PDB; 5H8G; X-ray; 2.00 A; A=1-333.
DR   PDB; 5HGV; X-ray; 2.05 A; B/D=340-352.
DR   PDB; 5M44; X-ray; 2.71 A; A=1-335.
DR   PDB; 5M4C; X-ray; 1.94 A; A=1-335.
DR   PDB; 5M4F; X-ray; 1.52 A; A=1-335.
DR   PDB; 5M4I; X-ray; 2.22 A; A=1-335.
DR   PDBsum; 1JWH; -.
DR   PDBsum; 1NA7; -.
DR   PDBsum; 1PJK; -.
DR   PDBsum; 2PVR; -.
DR   PDBsum; 2ZJW; -.
DR   PDBsum; 3AMY; -.
DR   PDBsum; 3AT2; -.
DR   PDBsum; 3AT3; -.
DR   PDBsum; 3AT4; -.
DR   PDBsum; 3AXW; -.
DR   PDBsum; 3BQC; -.
DR   PDBsum; 3C13; -.
DR   PDBsum; 3FWQ; -.
DR   PDBsum; 3H30; -.
DR   PDBsum; 3JUH; -.
DR   PDBsum; 3MB6; -.
DR   PDBsum; 3MB7; -.
DR   PDBsum; 3NGA; -.
DR   PDBsum; 3NSZ; -.
DR   PDBsum; 3OWJ; -.
DR   PDBsum; 3OWK; -.
DR   PDBsum; 3OWL; -.
DR   PDBsum; 3PE1; -.
DR   PDBsum; 3PE2; -.
DR   PDBsum; 3PE4; -.
DR   PDBsum; 3Q04; -.
DR   PDBsum; 3Q9W; -.
DR   PDBsum; 3Q9X; -.
DR   PDBsum; 3Q9Y; -.
DR   PDBsum; 3Q9Z; -.
DR   PDBsum; 3QA0; -.
DR   PDBsum; 3R0T; -.
DR   PDBsum; 3RPS; -.
DR   PDBsum; 3TAX; -.
DR   PDBsum; 3U4U; -.
DR   PDBsum; 3U87; -.
DR   PDBsum; 3U9C; -.
DR   PDBsum; 3W8L; -.
DR   PDBsum; 3WAR; -.
DR   PDBsum; 3WIK; -.
DR   PDBsum; 3WIL; -.
DR   PDBsum; 3WOW; -.
DR   PDBsum; 4DGL; -.
DR   PDBsum; 4FBX; -.
DR   PDBsum; 4GRB; -.
DR   PDBsum; 4GUB; -.
DR   PDBsum; 4GYW; -.
DR   PDBsum; 4GYY; -.
DR   PDBsum; 4GZ3; -.
DR   PDBsum; 4IB5; -.
DR   PDBsum; 4KWP; -.
DR   PDBsum; 4MD7; -.
DR   PDBsum; 4MD8; -.
DR   PDBsum; 4MD9; -.
DR   PDBsum; 4NH1; -.
DR   PDBsum; 4RLL; -.
DR   PDBsum; 4UB7; -.
DR   PDBsum; 4UBA; -.
DR   PDBsum; 5B0X; -.
DR   PDBsum; 5CLP; -.
DR   PDBsum; 5CQU; -.
DR   PDBsum; 5CQW; -.
DR   PDBsum; 5CS6; -.
DR   PDBsum; 5CSH; -.
DR   PDBsum; 5CSP; -.
DR   PDBsum; 5CSV; -.
DR   PDBsum; 5CT0; -.
DR   PDBsum; 5CTP; -.
DR   PDBsum; 5CU0; -.
DR   PDBsum; 5CU2; -.
DR   PDBsum; 5CU3; -.
DR   PDBsum; 5CU4; -.
DR   PDBsum; 5CU6; -.
DR   PDBsum; 5CVF; -.
DR   PDBsum; 5CVG; -.
DR   PDBsum; 5CVH; -.
DR   PDBsum; 5CX9; -.
DR   PDBsum; 5H8B; -.
DR   PDBsum; 5H8E; -.
DR   PDBsum; 5H8G; -.
DR   PDBsum; 5HGV; -.
DR   PDBsum; 5M44; -.
DR   PDBsum; 5M4C; -.
DR   PDBsum; 5M4F; -.
DR   PDBsum; 5M4I; -.
DR   ProteinModelPortal; P68400; -.
DR   SMR; P68400; -.
DR   BioGrid; 107841; 443.
DR   DIP; DIP-32682N; -.
DR   IntAct; P68400; 277.
DR   MINT; MINT-142347; -.
DR   STRING; 9606.ENSP00000217244; -.
DR   BindingDB; P68400; -.
DR   ChEMBL; CHEMBL3629; -.
DR   DrugBank; DB03127; Benzamidine.
DR   DrugBank; DB08846; Ellagic Acid.
DR   DrugBank; DB04395; Phosphoaminophosphonic Acid-Adenylate Ester.
DR   DrugBank; DB02709; Resveratrol.
DR   DrugBank; DB04462; Tetrabromo-2-Benzotriazole.
DR   GuidetoPHARMACOLOGY; 1549; -.
DR   iPTMnet; P68400; -.
DR   PhosphoSitePlus; P68400; -.
DR   SwissPalm; P68400; -.
DR   BioMuta; CSNK2A1; -.
DR   DMDM; 55977123; -.
DR   EPD; P68400; -.
DR   MaxQB; P68400; -.
DR   PaxDb; P68400; -.
DR   PeptideAtlas; P68400; -.
DR   PRIDE; P68400; -.
DR   DNASU; 1457; -.
DR   Ensembl; ENST00000217244; ENSP00000217244; ENSG00000101266. [P68400-1]
DR   Ensembl; ENST00000349736; ENSP00000339247; ENSG00000101266. [P68400-1]
DR   Ensembl; ENST00000400217; ENSP00000383076; ENSG00000101266. [P68400-2]
DR   GeneID; 1457; -.
DR   KEGG; hsa:1457; -.
DR   UCSC; uc002wdw.2; human. [P68400-1]
DR   CTD; 1457; -.
DR   DisGeNET; 1457; -.
DR   GeneCards; CSNK2A1; -.
DR   HGNC; HGNC:2457; CSNK2A1.
DR   HPA; CAB020680; -.
DR   HPA; CAB069395; -.
DR   HPA; HPA059206; -.
DR   MIM; 115440; gene.
DR   MIM; 617062; phenotype.
DR   neXtProt; NX_P68400; -.
DR   OpenTargets; ENSG00000101266; -.
DR   PharmGKB; PA26957; -.
DR   eggNOG; KOG0668; Eukaryota.
DR   eggNOG; ENOG410XNPP; LUCA.
DR   GeneTree; ENSGT00390000004215; -.
DR   HOGENOM; HOG000233021; -.
DR   HOVERGEN; HBG107282; -.
DR   InParanoid; P68400; -.
DR   KO; K03097; -.
DR   PhylomeDB; P68400; -.
DR   TreeFam; TF300483; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   Reactome; R-HSA-1483191; Synthesis of PC.
DR   Reactome; R-HSA-201688; WNT mediated activation of DVL.
DR   Reactome; R-HSA-2514853; Condensation of Prometaphase Chromosomes.
DR   Reactome; R-HSA-445144; Signal transduction by L1.
DR   Reactome; R-HSA-6804756; Regulation of TP53 Activity through Phosphorylation.
DR   Reactome; R-HSA-6814122; Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding.
DR   SignaLink; P68400; -.
DR   SIGNOR; P68400; -.
DR   ChiTaRS; CSNK2A1; human.
DR   EvolutionaryTrace; P68400; -.
DR   GeneWiki; Casein_kinase_2,_alpha_1; -.
DR   GenomeRNAi; 1457; -.
DR   PMAP-CutDB; B4DYS6; -.
DR   PRO; PR:P68400; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   Bgee; ENSG00000101266; -.
DR   CleanEx; HS_CSNK2A1; -.
DR   ExpressionAtlas; P68400; baseline and differential.
DR   Genevisible; P68400; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0016581; C:NuRD complex; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; TAS:ProtInc.
DR   GO; GO:0005956; C:protein kinase CK2 complex; IDA:CAFA.
DR   GO; GO:0016580; C:Sin3 complex; IDA:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0051879; F:Hsp90 protein binding; TAS:UniProtKB.
DR   GO; GO:0016301; F:kinase activity; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0047485; F:protein N-terminus binding; IPI:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0061077; P:chaperone-mediated protein folding; TAS:UniProtKB.
DR   GO; GO:0071174; P:mitotic spindle checkpoint; IMP:UniProtKB.
DR   GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; IMP:UniProtKB.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; IDA:CAFA.
DR   GO; GO:0006656; P:phosphatidylcholine biosynthetic process; TAS:Reactome.
DR   GO; GO:0030307; P:positive regulation of cell growth; IDA:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IDA:UniProtKB.
DR   GO; GO:0045732; P:positive regulation of protein catabolic process; IDA:UniProtKB.
DR   GO; GO:0030177; P:positive regulation of Wnt signaling pathway; IMP:UniProtKB.
DR   GO; GO:0006457; P:protein folding; TAS:Reactome.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; TAS:Reactome.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0048511; P:rhythmic process; IEA:UniProtKB-KW.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0016055; P:Wnt signaling pathway; IEA:UniProtKB-KW.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Apoptosis; ATP-binding;
KW   Biological rhythms; Cell cycle; Complete proteome; Disease mutation;
KW   Kinase; Mental retardation; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Polymorphism; Reference proteome;
KW   Serine/threonine-protein kinase; Transcription;
KW   Transcription regulation; Transferase; Wnt signaling pathway.
FT   CHAIN         1    391       Casein kinase II subunit alpha.
FT                                /FTId=PRO_0000085883.
FT   DOMAIN       39    324       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND      45     53       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION       36     41       Interaction with beta subunit.
FT                                {ECO:0000250}.
FT   ACT_SITE    156    156       Proton acceptor.
FT   BINDING      68     68       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     344    344       Phosphothreonine; by CDK1.
FT                                {ECO:0000269|PubMed:7592773}.
FT   MOD_RES     360    360       Phosphothreonine; by CDK1.
FT                                {ECO:0000269|PubMed:7592773}.
FT   MOD_RES     362    362       Phosphoserine; by CDK1.
FT                                {ECO:0000269|PubMed:7592773}.
FT   MOD_RES     370    370       Phosphoserine; by CDK1.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000269|PubMed:7592773}.
FT   VAR_SEQ       1    136       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_041925.
FT   VARIANT      47     47       R -> Q (in OCNDS).
FT                                {ECO:0000269|PubMed:27048600}.
FT                                /FTId=VAR_077045.
FT   VARIANT      50     50       Y -> S (in OCNDS).
FT                                {ECO:0000269|PubMed:27048600}.
FT                                /FTId=VAR_077046.
FT   VARIANT     175    175       D -> G (in OCNDS).
FT                                {ECO:0000269|PubMed:27048600}.
FT                                /FTId=VAR_077047.
FT   VARIANT     198    198       K -> R (in OCNDS).
FT                                {ECO:0000269|PubMed:27048600}.
FT                                /FTId=VAR_077048.
FT   CONFLICT    128    128       L -> F (in Ref. 3; CAA49758).
FT                                {ECO:0000305}.
FT   CONFLICT    256    256       D -> G (in Ref. 3; CAA49758).
FT                                {ECO:0000305}.
FT   CONFLICT    287    287       S -> R (in Ref. 3; CAA49758).
FT                                {ECO:0000305}.
FT   CONFLICT    351    351       M -> V (in Ref. 3; CAA49758).
FT                                {ECO:0000305}.
FT   STRAND       10     12       {ECO:0000244|PDB:3WAR}.
FT   TURN         13     18       {ECO:0000244|PDB:3WAR}.
FT   HELIX        21     24       {ECO:0000244|PDB:3WAR}.
FT   HELIX        26     28       {ECO:0000244|PDB:3WAR}.
FT   HELIX        36     38       {ECO:0000244|PDB:3WAR}.
FT   STRAND       39     47       {ECO:0000244|PDB:3WAR}.
FT   STRAND       49     58       {ECO:0000244|PDB:3WAR}.
FT   TURN         59     61       {ECO:0000244|PDB:3WAR}.
FT   STRAND       64     70       {ECO:0000244|PDB:3WAR}.
FT   TURN         72     74       {ECO:0000244|PDB:5CU6}.
FT   HELIX        75     88       {ECO:0000244|PDB:3WAR}.
FT   STRAND       97    102       {ECO:0000244|PDB:3WAR}.
FT   TURN        104    106       {ECO:0000244|PDB:3WAR}.
FT   STRAND      107    114       {ECO:0000244|PDB:3WAR}.
FT   TURN        118    120       {ECO:0000244|PDB:5CVG}.
FT   HELIX       121    124       {ECO:0000244|PDB:3WAR}.
FT   HELIX       125    127       {ECO:0000244|PDB:3WAR}.
FT   HELIX       130    149       {ECO:0000244|PDB:3WAR}.
FT   HELIX       159    161       {ECO:0000244|PDB:3WAR}.
FT   STRAND      162    165       {ECO:0000244|PDB:3WAR}.
FT   HELIX       166    168       {ECO:0000244|PDB:3WAR}.
FT   STRAND      170    173       {ECO:0000244|PDB:3WAR}.
FT   HELIX       176    178       {ECO:0000244|PDB:5CVG}.
FT   HELIX       195    197       {ECO:0000244|PDB:3WAR}.
FT   HELIX       200    203       {ECO:0000244|PDB:3WAR}.
FT   HELIX       212    227       {ECO:0000244|PDB:3WAR}.
FT   STRAND      230    233       {ECO:0000244|PDB:3WAR}.
FT   HELIX       238    249       {ECO:0000244|PDB:3WAR}.
FT   HELIX       251    261       {ECO:0000244|PDB:3WAR}.
FT   HELIX       267    269       {ECO:0000244|PDB:3WAR}.
FT   TURN        270    272       {ECO:0000244|PDB:3WAR}.
FT   HELIX       281    284       {ECO:0000244|PDB:3WAR}.
FT   TURN        287    289       {ECO:0000244|PDB:3WAR}.
FT   HELIX       290    292       {ECO:0000244|PDB:3WAR}.
FT   HELIX       295    304       {ECO:0000244|PDB:3WAR}.
FT   HELIX       309    311       {ECO:0000244|PDB:3WAR}.
FT   HELIX       315    318       {ECO:0000244|PDB:3WAR}.
FT   HELIX       322    324       {ECO:0000244|PDB:3WAR}.
FT   HELIX       325    331       {ECO:0000244|PDB:3WAR}.
FT   STRAND      333    335       {ECO:0000244|PDB:1JWH}.
SQ   SEQUENCE   391 AA;  45144 MW;  D3B6F5D13FF7422D CRC64;
     MSGPVPSRAR VYTDVNTHRP REYWDYESHV VEWGNQDDYQ LVRKLGRGKY SEVFEAINIT
     NNEKVVVKIL KPVKKKKIKR EIKILENLRG GPNIITLADI VKDPVSRTPA LVFEHVNNTD
     FKQLYQTLTD YDIRFYMYEI LKALDYCHSM GIMHRDVKPH NVMIDHEHRK LRLIDWGLAE
     FYHPGQEYNV RVASRYFKGP ELLVDYQMYD YSLDMWSLGC MLASMIFRKE PFFHGHDNYD
     QLVRIAKVLG TEDLYDYIDK YNIELDPRFN DILGRHSRKR WERFVHSENQ HLVSPEALDF
     LDKLLRYDHQ SRLTAREAME HPYFYTVVKD QARMGSSSMP GGSTPVSSAN MMSGISSVPT
     PSPLGPLAGS PVIAAANPLG MPVPAAAGAQ Q
//
